These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1238 related articles for article (PubMed ID: 26198808)

  • 1. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
    Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
    Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
    Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
    Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal aflibercept for diabetic macular edema.
    Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
    Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
    Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
    Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
    Ruiz-Moreno JM
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies.
    Korobelnik JF; Lu C; Katz TA; Dhoot DS; Loewenstein A; Arnold J; Staurenghi G
    Ophthalmol Retina; 2019 Aug; 3(8):663-669. PubMed ID: 31103642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
    Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
    Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
    Heier JS; Clark WL; Boyer DS; Brown DM; Vitti R; Berliner AJ; Kazmi H; Ma Y; Stemper B; Zeitz O; Sandbrink R; Haller JA
    Ophthalmology; 2014 Jul; 121(7):1414-1420.e1. PubMed ID: 24679444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.
    Do DV; Nguyen QD; Boyer D; Schmidt-Erfurth U; Brown DM; Vitti R; Berliner AJ; Gao B; Zeitz O; Ruckert R; Schmelter T; Sandbrink R; Heier JS;
    Ophthalmology; 2012 Aug; 119(8):1658-65. PubMed ID: 22537617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
    Campochiaro PA; Clark WL; Boyer DS; Heier JS; Brown DM; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Haller JA
    Ophthalmology; 2015 Mar; 122(3):538-44. PubMed ID: 25315663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
    Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
    Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in Patients with Diabetic Macular Edema Requiring Cataract Surgery in VISTA and VIVID Studies.
    Moshfeghi AA; Thompson D; Berliner AJ; Saroj N
    Ophthalmol Retina; 2020 May; 4(5):481-485. PubMed ID: 31924543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.
    Dhoot DS; Moini H; Reed K; Du W; Vitti R; Berliner AJ; Singh RP
    Eye (Lond); 2023 Jul; 37(10):2020-2025. PubMed ID: 35440699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.
    Gonzalez VH; Boyer DS; Schmidt-Erfurth U; Heier JS; Gordon C; Benz MS; Marcus DM; Sabates NR; Vitti R; Kazmi H; Berliner AJ; Soo Y; Zhu X; Moini H; Zeitz O; Sandbrink R; Do DV
    Retina; 2015 Apr; 35(4):687-94. PubMed ID: 25621943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
    Ehlers JP; Uchida A; Hu M; Figueiredo N; Kaiser PK; Heier JS; Brown DM; Boyer DS; Do DV; Gibson A; Saroj N; Srivastava SK
    Ophthalmol Retina; 2019 Dec; 3(12):1056-1066. PubMed ID: 31473172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN.
    Terasaki H; Shiraki K; Ohji M; Metzig C; Schmelter T; Zeitz O; Sowade O; Kobayashi M; Vitti R; Berliner A; Shiraga F
    Retina; 2019 May; 39(5):938-947. PubMed ID: 29470308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
    Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
    Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
    Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
    Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study.
    Wykoff CC; Shah C; Dhoot D; Coleman HR; Thompson D; Du W; Baker K; Vitti R; Berliner AJ; Metzig C; Saroj N
    Ophthalmology; 2019 Aug; 126(8):1171-1180. PubMed ID: 30946887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.